Alexander Bachmann1, Andrea Tubaro2, Neil Barber3, Frank d'Ancona4, Gordon Muir5, Ulrich Witzsch6, Marc-Oliver Grimm7, Joan Benejam8, Jens-Uwe Stolzenburg9, Antony Riddick10, Sascha Pahernik11, Herman Roelink12, Filip Ameye13, Christian Saussine14, Franck Bruyère15, Wolfgang Loidl16, Tim Larner17, Nirjan-Kumar Gogoi18, Richard Hindley19, Rolf Muschter20, Andrew Thorpe21, Nitin Shrotri22, Stuart Graham23, Moritz Hamann24, Kurt Miller25, Martin Schostak26, Carlos Capitán27, Helmut Knispel28, J Andrew Thomas29. 1. Department of Urology Basel, University Hospital Basel, University Basel, Basel, Switzerland. Electronic address: Alexander.Bachmann@usb.ch. 2. Department of Urology, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy. 3. Department of Urology, Frimley Park Hospital, Frimley, Camberley, UK. 4. Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. 5. Department of Urology, King's College Hospital and King's Health Partners, London, UK. 6. Department of Urology and Paediatric Urology, Krankenhaus Nordwest, Frankfurt, Germany. 7. Department of Urology, University Hospital of Jena, Jena, Germany. 8. Department of Urology, Hospital de Manacor, Manacor, Spain. 9. Department of Urology, Universitätsklinikum Leipzig, Leipzig, Germany. 10. Department of Urology, Lothian University Hospitals Division, Western General Hospital, Edinburgh, UK. 11. Department of Urology, University Hospital of Heidelberg, Heidelberg, Germany. 12. Department of Urology, Ziekenhuis Groep Twente, Almelo/Hengelo, The Netherlands. 13. Department of Urology, AZ Maria Middelares Gent, Gent, Belgium. 14. Department of Urology, Nouvel Hôpital Civil de Strasbourg, Strasbourg University, Strasbourg, France. 15. Department of Urology, CHRU Bretonneau, Tours, Loire Valley, and Université François Rabelais de Tours, PRES Centre-Val de Loire Université, Tours, France. 16. Department of Urology, Krankenhaus der Barmherzigen Schwestern Linz, Linz, Austria. 17. Department of Urology, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK. 18. Department of Urology, Mid Yorkshire NHS Trust, Dewsbury & District Hospital, Dewsbury, UK. 19. Department of Urology, Basingstoke and North Hampshire NHS Foundation Trust, Hampshire, UK. 20. Department of Urology, Diakoniekrankenhaus Rotenburg, Rotenburg, Germany. 21. Department of Urology, Freeman Hospital Newcastle, Newcastle upon Tyne, UK. 22. Department of Urology, Kent and Canterbury Hospital, Kent, UK. 23. Department of Urology, Whipps Cross University Hospital, London, UK. 24. Department of Urology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany. 25. Department of Urology, Charité, Berlin, Germany. 26. Department of Urology, University Hospital Magdeburg, Magdeburg, Germany. 27. Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain. 28. Department of Urology, Uro-Forschungs GmbH im St. Hedwig Krankenhaus, Berlin, Germany. 29. Department of Urology, ABMU LHB, Princess of Wales Hospital, Bridgend, Wales, UK.
Abstract
BACKGROUND: The comparative outcome with GreenLight (GL) photoselective vaporisation of the prostate and transurethral resection of the prostate (TURP) in men with lower urinary tract symptoms due to benign prostatic obstruction (BPO) has been questioned. OBJECTIVE: The primary objective of the GOLIATH study was to evaluate the noninferiority of 180-W GL XPS (XPS) to TURP for International Prostate Symptom Score (IPSS) and maximum flow rate (Qmax) at 6 mo and the proportion of patients who were complication free. DESIGN, SETTING, AND PARTICIPANTS: Prospective randomised controlled trial at 29 centres in 9 European countries involving 281 patients with BPO. INTERVENTION: 180-W GL XPS system or TURP. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Measurements used were IPSS, Qmax, prostate volume (PV), postvoid residual (PVR) and complications, perioperative parameters, and reintervention rates. Noninferiority was evaluated using one-sided tests at the 2.5% level of significance. The statistical significance of other comparisons was assessed at the (two-sided) 5% level. RESULTS AND LIMITATIONS: The study demonstrated the noninferiority of XPS to TURP for IPSS, Qmax, and complication-free proportion. PV and PVR were comparable between groups. Time until stable health status, length of catheterisation, and length of hospital stay were superior with XPS (p<0.001). Early reintervention rate within 30 d was three times higher after TURP (p=0.025); however, the overall postoperative reintervention rates were not significantly different between treatment arms. A limitation was the short follow-up. CONCLUSIONS:XPS was shown to be noninferior (comparable) to TURP in terms of IPSS, Qmax, and proportion of patients free of complications. XPS results in a lower rate of early reinterventions but has a similar rate after 6 mo. TRIAL REGISTRATION: ClinicalTrials.gov, identifier NCT01218672.
RCT Entities:
BACKGROUND: The comparative outcome with GreenLight (GL) photoselective vaporisation of the prostate and transurethral resection of the prostate (TURP) in men with lower urinary tract symptoms due to benign prostatic obstruction (BPO) has been questioned. OBJECTIVE: The primary objective of the GOLIATH study was to evaluate the noninferiority of 180-W GL XPS (XPS) to TURP for International Prostate Symptom Score (IPSS) and maximum flow rate (Qmax) at 6 mo and the proportion of patients who were complication free. DESIGN, SETTING, AND PARTICIPANTS: Prospective randomised controlled trial at 29 centres in 9 European countries involving 281 patients with BPO. INTERVENTION: 180-W GL XPS system or TURP. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Measurements used were IPSS, Qmax, prostate volume (PV), postvoid residual (PVR) and complications, perioperative parameters, and reintervention rates. Noninferiority was evaluated using one-sided tests at the 2.5% level of significance. The statistical significance of other comparisons was assessed at the (two-sided) 5% level. RESULTS AND LIMITATIONS: The study demonstrated the noninferiority of XPS to TURP for IPSS, Qmax, and complication-free proportion. PV and PVR were comparable between groups. Time until stable health status, length of catheterisation, and length of hospital stay were superior with XPS (p<0.001). Early reintervention rate within 30 d was three times higher after TURP (p=0.025); however, the overall postoperative reintervention rates were not significantly different between treatment arms. A limitation was the short follow-up. CONCLUSIONS: XPS was shown to be noninferior (comparable) to TURP in terms of IPSS, Qmax, and proportion of patients free of complications. XPS results in a lower rate of early reinterventions but has a similar rate after 6 mo. TRIAL REGISTRATION: ClinicalTrials.gov, identifier NCT01218672.
Authors: Marian S Wettstein; Clinsy Pazhepurackel; Aline S Neumann; Dixon T S Woon; Jaime O Herrera-Caceres; Marko Kozomara; Cédric Poyet; Tullio Sulser; Girish S Kulkarni; Thomas Hermanns Journal: World J Urol Date: 2019-05-13 Impact factor: 4.226